|
Document And Entity Information
|
9 Months Ended | |
|---|---|---|
|
Sep. 30, 2012
|
Nov. 01, 2012
|
|
| Document and Entity Information [Abstract] | ||
| Entity Registrant Name | PDL BIOPHARMA, INC. | |
| Document Type | 10-Q | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Common Stock, Shares Outstanding | 139,933,204 | |
| Amendment Flag | false | |
| Entity Central Index Key | 0000882104 | |
| Entity Current Reporting Status | Yes | |
| Entity Voluntary Filers | No | |
| Entity Filer Category | Large Accelerated Filer | |
| Entity Well-known Seasoned Issuer | Yes | |
| Document Period End Date | Sep. 30, 2012 | |
| Document Fiscal Year Focus | 2012 | |
| Document Fiscal Period Focus | Q3 |
| X | ||||||||||
|
- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document. No definition available.
|
| X | ||||||||||
|
- Definition
End date of current fiscal year in the format --MM-DD. No definition available.
|
| X | ||||||||||
|
- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. No definition available.
|
| X | ||||||||||
|
- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. No definition available.
|
| X | ||||||||||
|
- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD. No definition available.
|
| X | ||||||||||
|
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other". No definition available.
|
| X | ||||||||||
|
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. No definition available.
|
| X | ||||||||||
|
- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. No definition available.
|
| X | ||||||||||
|
- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. No definition available.
|
| X | ||||||||||
|
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. No definition available.
|
| X | ||||||||||
|
- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. No definition available.
|
| X | ||||||||||
|
- Details
|
|
Condensed Consolidated Statements Of Income (Unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Revenues | ||||
| Royalties | $ 85,231 | $ 83,370 | $ 288,479 | $ 278,833 |
| License and other | 400 | 10,400 | ||
| Total revenues | 85,231 | 83,770 | 288,479 | 289,233 |
| Operating expenses | ||||
| General and administrative | 5,647 | 3,960 | 17,737 | 13,516 |
| Operating income | 79,584 | 79,810 | 270,742 | 275,717 |
| Non-operating expense, net | ||||
| Loss on retirement or conversion of convertible notes | (766) | |||
| Interest and other income, net | 1,867 | 130 | 2,385 | 463 |
| Interest expense | (6,514) | (9,007) | (23,087) | (27,941) |
| Total non-operating expense, net | (4,647) | (8,877) | (20,702) | (28,244) |
| Income before income taxes | 74,937 | 70,933 | 250,040 | 247,473 |
| Income tax expense | 26,362 | 25,017 | 87,779 | 87,026 |
| Net income | $ 48,575 | $ 45,916 | $ 162,261 | $ 160,447 |
| Net income per share | ||||
| Basic (in Dollars per share) | $ 0.35 | $ 0.33 | $ 1.16 | $ 1.15 |
| Diluted (in Dollars per share) | $ 0.32 | $ 0.28 | $ 1.08 | $ 0.88 |
| Weighted average shares outstanding | ||||
| Basic (in Shares) | 139,715 | 139,680 | 139,693 | 139,665 |
| Diluted (in Shares) | 149,626 | 167,019 | 150,678 | 186,756 |
| Cash dividends declared per common share (in Dollars per share) | $ 0.60 | $ 0.60 | ||
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Aggregate dividends declared during the period for each share of common stock outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cost of borrowed funds accounted for as interest that was charged against earnings during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents investment income derived from investments in debt and equity securities consisting of interest income earned from investments in debt securities and on cash and cash equivalents, dividend income from investments in equity securities, and income or expense derived from the amortization of investment related discounts or premiums, respectively, net of related investment expenses. This item does not include realized or unrealized gains or losses on the sale or holding of investments in debt and equity securities required to be included in earnings for the period or for other than temporary losses related to investments in debt and equity securities which are included in realized losses in the period recognized, and does not include investment income from real or personal property, such as rental income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Definition
Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Condensed Consolidated Statements Of Comprehensive Income (Unaudited) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Net income | $ 48,575 | $ 45,916 | $ 162,261 | $ 160,447 |
| Other comprehensive income (loss), net of tax | ||||
| Unrealized losses on investments in available-for-sale securities | (14) | (55) | (1) | (8) |
| Unrealized gains (losses) on cash flow hedges | (3,126) | 4,281 | (853) | (4,981) |
| Total other comprehensive income (loss), net of tax | (3,140) | 4,226 | (854) | (4,989) |
| Comprehensive income | $ 45,435 | $ 50,142 | $ 161,407 | $ 155,458 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net of tax amount of other comprehensive income (loss) attributable to both parent entity and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net of tax amount, before reclassification adjustments, of the change in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges. Also includes an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net of tax amount of unrealized holding gain (loss) before reclassification adjustments and transfers on available-for-sale securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
An amount representing an agreement for an unconditional promise by the maker to pay the Company (holder) a definite sum of money within one year from the balance sheet date (or the normal operating cycle, whichever is longer), net of any write-downs taken for collection uncertainty on the part of the holder. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date more than one year from the balance sheet date, net of any write-downs taken for collection uncertainty on the part of the holder. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value of the current portion of notes payable which were initially due after one year or beyond the normal operating cycle, if longer, and which are not otherwise defined in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Condensed Consolidated Balance Sheets (Parentheticals) (USD $)
In Thousands, except Per Share data, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Preferred stock par value (in Dollars per share) | $ 0.01 | $ 0.01 |
| Preferred stock, shares authorized (in Shares) | 10,000 | 10,000 |
| Preferred stock, shares issued (in Shares) | 0 | 0 |
| Preferred stock, shares outstanding (in Shares) | 0 | 0 |
| Common stock par value (in Dollars per share) | $ 0.01 | $ 0.01 |
| Common stock, shares authorized (in Shares) | 250,000 | 250,000 |
| Common stock, shares issued (in Shares) | 139,724 | 139,680 |
| Common stock, shares outstanding (in Shares) | 139,724 | 139,680 |
| X | ||||||||||
|
- Definition
Face amount or stated value of common stock per share; generally not indicative of the fair market value per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net change during the reporting period in accrued legal settlement expense. No definition available.
|
| X | ||||||||||
|
- Definition
Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net amount of deferred income taxes and income tax credits less the tax benefit from exercise of stock options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of the aggregate tax benefit realized from the exercise of stock options and the conversion of similar instruments during the annual period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net gain (loss) during the reporting period due to ineffectiveness in foreign currency cash flow hedges. Recognized in earnings. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other expenses incurred but not yet paid. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows. No definition available.
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash paid for interest during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net cash inflow or outflow from financing activity for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net cash inflow or outflow from investing activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow associated with maturities (principal being due), prepayments and calls (requests of early payments) on securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Note 1 - Summary of Significant Accounting Policies
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Basis of Presentation and Significant Accounting Policies [Text Block] |
Basis
of Presentation
The
accompanying unaudited Condensed Consolidated Financial
Statements have been prepared in accordance with U.S.
generally accepted accounting principles (GAAP) for interim
financial information. The financial statements include all
adjustments (consisting only of normal recurring
adjustments) the management of PDL BioPharma, Inc. (the
Company, PDL, we, us or our) believes are necessary for a
fair presentation of the periods presented. These interim
financial results are not necessarily indicative of results
expected for the full fiscal year or for any subsequent
interim period.
The
accompanying Condensed Consolidated Financial Statements
and related financial information should be read in
conjunction with the audited Consolidated Financial
Statements and the related notes thereto for the year ended
December 31, 2011, included in our Annual Report on Form
10-K filed with the U.S. Securities and Exchange
Commission. The Condensed Consolidated Balance Sheet at
December 31, 2011, has been derived from the audited
Consolidated Financial Statements at that date.
Principles
of Consolidation
The
Consolidated Financial Statements include the accounts of
PDL and its wholly-owned subsidiaries. All material
intercompany balances and transactions have been eliminated
in consolidation.
Notes
Receivable
We
account for our notes receivable at amortized cost, net of
unamortized origination fees, if any. Related
fees and costs are recorded net of amounts
reimbursed. Interest is accreted or accrued to
interest income using the interest method.
Customer
Concentration
The
percentage of total revenue earned from our
licensees’ net product sales, which individually
accounted for ten percent or more of our total revenues,
was:
Foreign
Currency Hedging
We
enter into foreign currency hedges to manage exposures
arising in the normal course of business and not for
speculative purposes.
We
hedge certain Euro-denominated currency exposures related
to our licensees’ product sales with Euro forward
contracts and, in 2011, Euro forward and option contracts.
In general, these contracts are intended to offset the
underlying Euro market risk in our royalty revenues. These
contracts extend through the fourth quarter of 2014. We
designate foreign currency exchange contracts used to hedge
royalty revenues based on underlying Euro-denominated sales
as cash flow hedges.
At
the inception of the hedging relationship and on a
quarterly basis, we assess hedge effectiveness. The fair
value of the Euro forward contracts is estimated using
pricing models with readily observable inputs from actively
quoted markets and is disclosed on a gross basis. The
aggregate unrealized gain or loss, net of tax, on the
effective portion of the hedge is recorded in
stockholders’ deficit as accumulated other
comprehensive income (loss). Gains or losses on cash flow
hedges are recognized as an adjustment to royalty revenue
in the same period that the hedged transaction impacts
earnings as royalty revenue. Any gain or loss on the
ineffective portions is reported in other income in the
period the ineffectiveness occurs.
During
the third quarter of 2012, we de-designated and terminated
a portion of our cash flow hedges. The gain realized was
reclassified from other comprehensive income (loss) to
other income in the third quarter. See Note 5 for
additional information on our foreign currency hedge
transactions.
Comprehensive
Income
In
the first quarter of 2012, we adopted Financial Accounting
Standards Board (FASB) accounting standard update (ASU)
2011-05, and have presented the components of other
comprehensive income (loss) in the Condensed Consolidated
Statements of Comprehensive Income. Also in accordance with
this ASU, we have applied this guidance retrospectively to
all periods presented. The adoption of the guidance was a
change to the presentation of other comprehensive income
(loss) and had no effect on our condensed consolidated
financial statements. See Note 14 for our discussion of
accumulated other comprehensive income (loss).
Recent
Accounting Pronouncements
In
December 2011, the FASB issued ASU 2011-11 requiring new
disclosures associated with offsetting financial
instruments and derivative instruments on the balance sheet
that will enable users to evaluate the effect on an
entity’s financial position. The ASU will be
effective in the first quarter of 2013, but is not expected
to have a material impact on our financial
statements.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. No definition available.
|
|
Note 2 - Net Income per Share
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings Per Share [Text Block] |
2.
Net Income per Share
We
compute net income per basic share using the
weighted-average number of shares of common stock
outstanding during the period less the weighted-average
number of restricted stock shares that are subject to
repurchase.
We
compute net income per diluted share using the sum of the
weighted-average number of common and common equivalent
shares outstanding. Common equivalent shares used in the
computation of net income per diluted share include shares
that may be issued under our stock options and restricted
stock awards, our 2.875% Convertible Senior Notes due
February 15, 2015 (February 2015 Notes), our 2.875%
Series 2012 Convertible Notes due February 15, 2015 (Series
2012 Notes), our 3.75% Senior Convertible Notes due May 1,
2015 (May 2015 Notes) and, in 2011, our 2.00% Convertible
Senior Notes due February 15, 2012 (2012 Notes), on a
weighted average basis for the period that the notes were
outstanding, including the effect of adding back interest
expense, net of tax, and the underlying shares using the
if-converted method. Our 2012 Notes were fully retired as
of September 30, 2011, and $179.0 million aggregate
principal amount of our February 2015 Notes was exchanged
for our Series 2012 Notes in the first quarter of
2012.
The
Series 2012 Notes and May 2015 Notes are net share settled,
with the principal amount settled in cash and the excess
settled in our common stock. The weighted-average share
adjustments related to our Series 2012 Notes and May 2015
Notes include the shares issuable in respect of such
excess. The May 2015 Notes had no dilutive effect for the
periods ended September 30, 2011. The conversion
price of the May 2015 Notes exceeded the market price of
our common stock for those periods so no stock was issuable
upon conversion.
We
excluded 19.2 million and 17.5 million shares of potential
dilution for our warrants for the periods ended September
30, 2012 and 2011, respectively, because the exercise price
of the warrants exceeded the average market price of our
common stock and thus, for the periods presented, no stock
was issuable upon conversion. These securities could be
dilutive in future periods. Our purchased call options will
always be anti-dilutive and therefore 22.6 million and 20.6
million shares were excluded for the periods ended
September 30, 2012 and 2011, respectively, because they
have no effect on diluted net income per share under
GAAP. For further information related to our
convertible notes, see Note 9.
We
excluded approximately 144,000 and 164,000 shares
underlying outstanding stock options, calculated on a
weighted average, from our net income per diluted share
calculations for the three and nine months ended September
30, 2012, respectively, and approximately 174,000 and
199,000 shares for the three and nine months ended
September 30, 2011, respectively, because their effect was
anti-dilutive.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for earnings per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 3 - Fair Value Measurements
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value Disclosures [Text Block] |
3. Fair Value
Measurements
The
fair value of our financial instruments are estimates of
the amounts that would be received if we were to sell an
asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement
date or exit price. The assets and liabilities are
categorized and disclosed in one of the following three
categories:
Level
1 – based on quoted market prices in active markets
for identical assets and liabilities;
Level
2 – based on quoted market prices for similar assets
and liabilities, using observable market based inputs or
unobservable market based inputs corroborated by market
data; and
Level
3 – based on unobservable inputs using
management’s best estimate and assumptions when
inputs are unavailable.
The
following tables present the fair value of our financial
instruments measured at fair value on a recurring basis by
level within the valuation hierarchy.
The
fair value of the certificate of deposit is priced using
quoted market prices for similar instruments, non-binding
market prices that are corroborated by observable market
data. The certificate of deposit is restricted as it was
purchased to collateralize the line of credit for Merus
Labs International, Inc., see Note 6.
Corporate
debt securities consist primarily of U.S. corporate bonds.
The fair value of corporate debt securities is estimated
using recently executed transactions or market quoted
prices, where observable. Independent pricing sources are
also used for valuation.
The
fair value of commercial paper is estimated based on
observable inputs of comparable securities.
The
fair value of foreign currency hedging contracts is
estimated based on pricing models using readily observable
inputs from actively quoted markets and is disclosed
on a gross basis.
The
following tables present the fair value of assets and
liabilities not subject to fair value recognition by level
within the valuation hierarchy:
As
of September 30, 2012, the fair values of our Merus Labs
Note Receivable, our Senior Secured Note Receivable, and
our Other Notes Receivable were determined using one or
more discounted cash flow models, incorporating expected
payments and the interest rate extended on the notes with
fixed interest rates and incorporating expected payments
for notes with a variable rate of return.
The
fair values of our convertible notes and our Non-recourse
Notes, as defined herein, were determined using quoted
market pricing or dealer quotes of our then outstanding
notes.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 4 - Cash Equivalents, Short-term and Long-term Investments
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash, Cash Equivalents, and Marketable Securities [Text Block] |
4.
Cash Equivalents and Investments
As
of September 30, 2012 and December 31, 2011, we had
invested our excess cash balances primarily in money market
funds, corporate debt securities, commercial paper, U.S.
government sponsored agency bonds and U.S. treasury
securities. Our securities are classified as
available-for-sale and are carried at estimated fair value,
with unrealized gains and losses, net of estimated taxes,
reported in accumulated other comprehensive income (loss)
in stockholders’ deficit. See Note 3 for fair value
measurement information. The cost of securities sold is
based on the specific identification method. To date, we
have not experienced credit losses on investments in these
instruments and we do not require collateral for our
investment activities.
We
recognized approximately $11,000 of gains on sales of
available-for-sale securities for the three and nine months
ended September 30, 2012. No gains or losses on sales of
available-for-sale securities were recognized for the
periods ended September 30, 2011. No significant facts or
circumstances have arisen to indicate that there has been
any deterioration in the creditworthiness of the issuers of
these securities. Based on our review of these securities,
we believe we had no other-than-temporary impairments on
these securities as of September 30, 2012 and December 31,
2011.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). No definition available.
|
|
Note 5 - Foreign Currency Hedging
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Derivative Instruments and Hedging Activities Disclosure [Text Block] |
5.
Foreign Currency Hedging
We
designate the foreign currency exchange contracts used to
hedge our royalty revenues based on underlying
Euro-denominated sales as cash flow hedges. Euro forward
contracts are presented on a net basis on our Condensed
Consolidated Balance Sheets as we have entered into a
netting arrangement with the counterparty. As of September
30, 2012 and December 31, 2011, all outstanding Euro
forward contracts and option contracts were classified as
cash flow hedges.
In
January 2012, we modified our existing Euro forward and
option contracts related to our licensees’ sales
through December 2012 into Euro forward contracts with more
favorable rates. Additionally, we entered into a series of
Euro forward contracts covering the quarters in which our
licensees’ sales occur through December 2013.
During
the third quarter of 2012, we reduced our forecasted
exposure to the Euro for 2013 royalties. We de-designated
and terminated certain forward contracts, due to our
determination that certain cash flow under
the de-designated contracts were probable to not
occur, and recorded a gain of approximately $391,000 to
other income, which was reclassified from other
comprehensive income (loss) net of tax effects.
The
termination of these contracts was effected through a
reduction in the notional amount of the original hedge
contracts which was then exchanged for new hedges of 2014
Euro-denominated royalties. These 2014 hedges were entered
into at a rate more favorable than the market rate as of
the date of the exchange.
The
notional amounts, Euro exchange rates, fair values of our
Euro forward contracts at September 30, 2012, and Euro
forward and option contracts at December 31, 2011,
designated as cash flow hedges were:
The
location and fair values of our Euro contracts in our
Condensed Consolidated Balance Sheets
were:
The
effect of our derivative instruments in our Condensed
Consolidated Statements of Income and our Condensed
Consolidated Statements of Comprehensive Income
were:
(1) Net
change in the fair value of the effective portion of cash
flow hedges classified in other comprehensive income (loss)
(OCI)
(2)
Effective portion classified as royalty revenue
(3)
Ineffective portion classified as interest and other
income, net
(4) Gain
on de-designation classified as interest and other income,
net
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for the entity's entire derivative instruments and hedging activities. Describes an entity's risk management strategies, derivatives in hedging activities and non-hedging derivative instruments, the assets, obligations, liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 6 - Notes and Other Long-term Receivables
|
9 Months Ended |
|---|---|
|
Sep. 30, 2012
|
|
| Loans, Notes, Trade and Other Receivables Disclosure [Text Block] |
6.
Notes and Other Long-term Receivables
Notes
and other long-term receivables included the following
significant agreements:
Merus
Labs Note Receivable and Credit Agreement
In
July 2012, PDL loaned $35.0 million to Merus Labs
International, Inc. (Merus Labs) in connection with its
acquisition of a commercial-stage pharmaceutical product
and related assets (the Assets). In addition, PDL agreed to
provide a $20.0 million letter of credit on behalf of Merus
Labs that the seller of the Assets may draw upon to satisfy
the remaining $20.0 million purchase price obligation on
July 11, 2013 (Letter of Credit). The Letter of Credit is
collateralized by a certificate of deposit reflected on our
balance sheet as restricted investment. Draws on the Letter
of Credit will be funded from the proceeds of an additional
loan to Merus Labs. Outstanding borrowings under the July
2012 loan to Merus Labs bear interest at the rate of 13.5%
per annum and outstanding borrowings as a result of draws
on the Letter of Credit bear interest at the rate of 14.0%
per annum, with all interest payable monthly. Merus Labs is
required to make annual principal payments of $5.0 million,
$7.5 million, $10.0 million, and $12.5 million in 2012,
2013, 2014, and 2015, respectively, with respect of the
July 2012 loan. The borrowings are subject to mandatory
prepayments upon certain asset dispositions or debt
issuances upon the terms set forth in the credit agreement
(Credit Agreement).
The
Credit Agreement provides for a number of standard events
of default, including payment, bankruptcy, covenant,
judgment and cross-defaults.
Senior
Secured Note Receivable
In
March 2012, the Company executed a $7.5 million two-year
senior secured note receivable (Senior Secured Note
Receivable). In addition to interest, the note gives PDL
certain rights to negotiate for certain royalty assets. The
note was recorded net of origination fees that are accreted
to the note receivable as interest income using the
interest method. The note bore interest at 10% per annum,
with interest due semi-annually and final interest due at
maturity together with the principal.
In
August 2012, PDL and the Borrower amended the note
receivable, providing a senior secured note receivable of
$10.0 million to replace the original $7.5 million note.
The principal of the note receivable will be repaid on
March 21, 2014. Interest will be paid on the
$10.0 million note receivable at a rate of 12% per annum
with interest payments due semi-annually in March and
September, and final interest due at maturity together with
the principal. The note was recorded net of origination
fees that are accreted to the note receivable as interest
income using the interest method. The Company has not
assigned a risk grade to the receivable or recorded an
allowance for credit loss as PDL anticipates all payments
will be received in full when due. No impairment has
been recorded as the payments on the note are
current.
For
fair value information related to our notes and other
long-term receivables, see Note 3.
|
| X | ||||||||||
|
- Definition
The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 7 - Accrued Liabilities
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounts Payable and Accrued Liabilities Disclosure [Text Block] |
7.
Accrued Liabilities
Accrued
liabilities consisted of the following:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 8 - Commitments and Contingencies
|
9 Months Ended |
|---|---|
|
Sep. 30, 2012
|
|
| Commitments and Contingencies Disclosure [Text Block] |
8.
Commitments and Contingencies
Legal
Proceedings
Communications
with Genentech regarding European SPCs
In
August 2010, we received a letter from Genentech, sent on
behalf of F. Hoffmann-LaRoche Ltd. (Roche) and Novartis AG
(Novartis), asserting that Avastin, Herceptin, Lucentis and
Xolair® (the
Genentech Products) do not infringe the supplementary
protection certificates (SPCs) granted to PDL by various
countries in Europe for each of the Genentech Products and
seeking a response from PDL to these assertions. Genentech
did not state what actions, if any, it intends to take with
respect to its assertions. PDL’s SPCs were granted by
the relevant national patent offices in Europe and
specifically cover the Genentech Products. The SPCs
covering the Genentech Products effectively extend our
European patent protection for our European Patent No. 0
451 216B generally until December 2014, except that the
SPCs for Herceptin will generally expire in July
2014.
Genentech’s
letter does not suggest that the Genentech Products do not
infringe PDL’s U.S. patents to the extent that such
Genentech Products are made, used or sold in the United
States (U.S.-based Sales). Genentech’s quarterly
royalty payments received after receipt of the letter
included royalties generated on all worldwide sales of the
Genentech Products.
If
Genentech is successful in asserting this position, then
under the terms of our license agreements with Genentech,
it would not owe us royalties on sales of the Genentech
Products that are both manufactured and sold outside of the
United States. Royalties on sale of the Genentech Products
that are made and sold outside of the United States
(ex-U.S.-based Manufacturing and Sales) accounted for
approximately 35% of our royalty revenues for the nine
months ended September 30, 2012. Based on announcements by
Roche regarding moving more manufacturing outside of the
United States, we expect this amount to increase in the
future.
We
believe that the SPCs are enforceable against the Genentech
Products, that Genentech’s letter violates the terms
of the 2003 settlement agreement and that Genentech owes us
royalties on sales of the Genentech Products on a worldwide
basis. We intend to vigorously assert our SPC-based patent
rights.
Nevada
Litigation with Genentech, Roche and Novartis in Nevada
State Court
In
August 2010, we filed a complaint in the Second Judicial
District of Nevada, Washoe County, naming Genentech, Roche
and Novartis as defendants. We intend to enforce our rights
under our 2003 settlement agreement with Genentech and are
seeking an order from the court declaring that Genentech is
obligated to pay royalties to us on ex-U.S.-based
Manufacturing and Sales of the Genentech Products.
The
2003 settlement agreement was entered into as part of a
definitive agreement resolving intellectual property
disputes between the two companies at that time. The
agreement limits Genentech’s ability to challenge
infringement of our patent rights and waives
Genentech’s right to challenge the validity of our
patent rights. Certain breaches of the 2003 settlement
agreement as alleged by our complaint require Genentech to
pay us liquidated and other damages of potentially greater
than one billion dollars. This amount includes a
retroactive royalty rate of 3.75% on past U.S.-based Sales
of the Genentech Products and interest, among other items.
We may also be entitled to either terminate our license
agreements with Genentech or be paid a flat royalty of
3.75% on future U.S.-based Sales of the Genentech
Products.
In
November 2010, Genentech and Roche filed a motion to
dismiss our complaint against them in which we seek to
enforce our rights under the 2003 settlement agreement with
Genentech. Genentech and Roche's motions to dismiss under
Nevada Rule of Civil Procedure 12(b)(5) alleged that all of
our claims for relief relating to the 2003 settlement
agreement should be dismissed because the 2003 settlement
agreement applies only to our U.S. patents. In addition,
Roche filed a separate motion to dismiss our complaint
under Nevada Rule of Civil Procedure 12(b)(2) on the ground
that the Nevada court lacks personal jurisdiction over
Roche. On July 7, 2011, the Second Judicial District Court
of Nevada ruled in favor of us on the two motions to
dismiss filed by Genentech and Roche. The court denied
Genentech and Roche's motion to dismiss four of our five
claims for relief and, further, denied Roche's separate
motion to dismiss for lack of personal jurisdiction. The
court dismissed one of our claims that Genentech committed
a bad-faith breach of the covenant of good faith and fair
dealing stating that, based on the current state of the
pleadings, no "special relationship" had been established
between Genentech and us as required under Nevada law. On
November 1, 2011, the Nevada court issued an order
accepting Roche’s stipulation of waiver to its
personal jurisdiction defense. As a result of the order,
Roche is foreclosed from reliance on lack of personal
jurisdiction in defending against our claims.
On
February 25, 2011, we reached a settlement with
Novartis under which, among other things, we agreed to
dismiss our claims against Novartis in the action in Nevada
state court against Genentech, Roche and Novartis.
Genentech and Roche continue to be parties to the Nevada
suit.
The
court has scheduled trial to commence on October 7, 2013,
however this date is likely to be extended. The outcome of
this litigation is uncertain and we may not be successful
in our allegations.
Lease
Guarantee
In
connection with the spin-off of Facet Biotech Corporation
(Facet) in 2008, we entered into amendments to the leases
for our former facilities in Redwood City, California,
under which Facet was added as a co-tenant under the
leases, and a Co-Tenancy Agreement, under which Facet
agreed to indemnify us for all matters related to the
leases attributable to the period after the spin-off date.
Should Facet default under its lease obligations, we would
be held liable by the landlord as a co-tenant and, thus, we
have in substance guaranteed the payments under the lease
agreements for the Redwood City facilities. As of September
30, 2012, the total lease payments for the duration of the
guarantee, which runs through December 2021, are
approximately $103.0 million. We would also be responsible
for lease-related costs including utilities, property taxes
and common area maintenance which may be as much as the
actual lease payments if Facet were to default. In April
2010, Abbott Laboratories acquired Facet and later renamed
the company Abbott Biotherapeutics Corp.
As
of September 30, 2012, and December 31, 2011, we had a
liability of $10.7 million on our Condensed Consolidated
Balance Sheets for the estimated fair value of this
guarantee. In future periods, we may increase the recorded
liability for this obligation if we conclude that a loss,
which is larger than the amount recorded, is both probable
and estimable.
|
| X | ||||||||||
|
- Definition
The entire disclosure for commitments and contingencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 9 - Convertible Notes and Non-recourse Notes
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Long-term Debt [Text Block] |
9.
Convertible Notes and Non-recourse Notes
As
of September 30, 2012, PDL was in compliance with all
applicable debt covenants, and embedded features of all
debt agreements were evaluated and did not need to be
accounted for separately. For fair value information on our
convertible notes and Non-recourse Notes, see Note
3.
Series
2012 Notes
In
January 2012, we exchanged $169.0 million aggregate
principal of new Series 2012 Notes for an identical
principal amount of our February 2015 Notes, plus a cash
payment of $5.00 for each $1,000 principal amount tendered,
totaling approximately $845,000. The cash incentive payment
was allocated to deferred issue costs of $765,000,
additional paid-in capital of $52,000 and deferred tax
assets of $28,000. The deferred issue costs will be
recognized over the life of the Series 2012 Notes as
interest expense. In February 2012, we entered into
separate privately negotiated exchange agreements under
which we exchanged an additional $10.0 million aggregate
principal amount of the new Series 2012 Notes for an
identical principal amount of our February 2015 Notes. At
the conclusion of these transactions, $1.0 million of our
February 2015 Notes remained outstanding.
The
terms of the Series 2012 Notes are governed by the
indenture dated as of January 5, 2012 (Indenture) and
include a net share settlement feature, meaning that if a
conversion occurs, the principal amount will be settled in
cash and the excess, if any, will be settled in the
Company’s common stock. The Series 2012 Notes may not
be redeemed by the Company prior to their stated maturity
date. Our Series 2012 Notes are due February 15, 2015 and
bear interest at a rate of 2.875% per annum, payable
semi-annually in arrears on February 15 and August 15 of
each year. This is the same interest rate that we pay on
the February 2015 Notes.
The
initial conversion rate of the Series 2012 Notes was
155.396 shares of common stock per $1,000 principal amount,
or approximately $6.44 per common share, subject to further
adjustment upon certain events including dividend payments.
Third party transaction costs of approximately $813,000
related to the exchange transactions have been recognized
within general and administrative expense, of which
$216,000 was recognized in the first quarter of 2012 and
$597,000 was recognized during the year ended December 31,
2011.
Holders
may convert their Series 2012 Notes at any time prior to
the close of business on the second scheduled trading day
immediately preceding the stated maturity date of the
Series 2012 Notes under the following circumstances:
Holders
of our Series 2012 Notes who convert their Series 2012
Notes in connection with a fundamental change resulting in
the reclassification, conversion, exchange or cancellation
of our common stock may be entitled to a make-whole premium
in the form of an increase in the conversion rate. Such
fundamental change is generally defined to include a merger
involving PDL, an acquisition of a majority of PDL’s
outstanding common stock and a change of a majority of
PDL’s board of directors without the approval of the
board of directors.
We
allocated $2.3 million of the remaining deferred February
2015 Notes original issue discount as of the date of the
exchange to the Series 2012 Notes based on the percentage
of the February 2015 Notes exchanged. In accordance with
the accounting guidance for convertible debt instruments
that may be settled in cash or other assets on conversion,
we were required to separately account for the liability
component of the instrument in a manner that reflects the
market interest rate for a similar nonconvertible
instrument at the date of issuance. As a result, we
separated the principal balance of the Series 2012 Notes,
net of the allocated original issue discount, between the
fair value of the debt component and the common stock
conversion feature. Using an assumed borrowing rate of
7.3%, which represents the estimated market interest rate
for a similar nonconvertible instrument available to us
during the period of the exchange transactions, we recorded
a total debt discount of $16.8 million, allocated $10.9
million to additional paid-in capital and $5.9 million to
deferred tax liability. The discount is being amortized to
interest expense over the term of the Series 2012 Notes and
increases interest expense during the term of the Series
2012 Notes from the 2.875% cash coupon interest rate to an
effective interest rate of 7.3%. The common stock
conversion feature is recorded as a component of
stockholders’ deficit.
The
principal amount, carrying value and unamortized discount
of our Series 2012 Notes were:
Interest
expense for our Series 2012 Notes on the Condensed
Consolidated Statements of Income was:
As
of September 30, 2012, our Series 2012 Notes are
convertible into 166.264 shares of the Company’s
common stock per $1,000 of principal amount, or
approximately $6.01 per common share, subject to further
adjustment upon certain events including dividend payments.
As of September 30, 2012, the remaining discount
amortization period was 2.4 years.
Our
common stock price did not exceed the conversion threshold
price of $7.98 per common share for at least 20 days during
the 30 consecutive trading days ended June 30, 2012;
accordingly the Series 2012 Notes were not convertible at
the option of the holder during the quarter ended September
30, 2012. Our common stock did not exceed the conversion
threshold price of $7.82 for at least 20 days during 30
consecutive trading days ended September 30, 2012;
accordingly the Series 2012 Notes are not convertible at
the option of the holder during the quarter ending December
31, 2012. At September 30, 2012, the if-converted value of
our Series 2012 Notes exceeded their principal amount by
approximately $50.2 million.
May
2015 Notes
As
of September 30, 2012, our May 2015 Notes are convertible
into 145.4893 shares of the Company’s common stock
per $1,000 of principal amount, or approximately $6.87 per
common share, subject to further adjustment upon certain
events including dividend payments. If a conversion occurs,
to the extent that the conversion value exceeds the
principal amount, the principal amount is due in cash and
the difference between the conversion value and the
principal amount is due in shares of the Company’s
common stock. As of September 30, 2012, the remaining
discount amortization period was 2.6 years.
The
principal amount, carrying value and unamortized discount
of our May 2015 Notes were:
Interest
expense for our May 2015 Notes on the Condensed
Consolidated Statements of Income was:
Our
common stock price did not exceed the conversion threshold
price of $9.12 per common share for at least 20 days during
the 30 consecutive trading days ended June 30, 2012;
accordingly the May 2015 Notes were not convertible at the
option of the holder during the quarter ended September 30,
2012. Our common stock did not exceed the conversion
threshold price of $8.94 for at least 20 days during 30
consecutive trading days ended September 30, 2012;
accordingly the May 2015 Notes are not convertible at the
option of the holder during the quarter ending December 31,
2012. At September 30, 2012, the if-converted value of our
May 2015 Notes exceeded their principal amount by
approximately $18.7 million.
Purchased
Call Options
At
September 30, 2012, the purchased call options cover,
subject to anti-dilution and certain other customary
adjustments substantially similar to those in our May 2015
Notes, approximately 22.6 million shares of our common
stock at a strike price of approximately $6.87, which
corresponds to the conversion price of our May 2015 Notes.
We may exercise the purchased call options upon conversion
of our May 2015 Notes and require the hedge counterparty to
deliver shares to the Company in an amount equal to the
shares required to be delivered by the Company to the note
holder for the excess conversion value.
Warrants
At
September 30, 2012, the outstanding warrants of up to 27.5
million shares of common stock underlying our May 2015
Notes, had a strike price of approximately $8.09 per share,
subject to additional anti-dilution and certain other
customary adjustments.
February
2015 Notes
As
of September 30, 2012, our February 2015 Notes aggregate
principal amount outstanding was $1.0 million, and were
convertible into 166.264 shares of common stock per $1,000
principal amount or approximately $6.01 per common share.
As of September 30, 2012, the remaining unamortized
issuance costs of approximately $14,000 and the unamortized
discount of approximately $10,000 are being amortized to
interest expense over the term of our February 2015 Notes,
with a remaining amortization period of approximately
2.4 years.
Non-recourse
Notes
As
of September 30, 2012, there was no remaining balance on
our Non-recourse Notes, as they were fully repaid on
September 17, 2012.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for long-term debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 10 - Other Long-Term Liabilities
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities Disclosure [Text Block] |
10.
Other Long-Term Liabilities
Other
long-term liabilities consisted of the following:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for other liabilities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 11 - Stock-Based Compensation
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Disclosure of Compensation Related Costs, Share-based Payments [Text Block] |
11.
Stock-Based Compensation
The
Company grants stock options and restricted stock awards
pursuant to a stockholder approved stock-based incentive
plan. This incentive plan is described in further detail in
Note 14, Stock-Based Compensation, of Notes to Consolidated
Financial Statements in the 2011 Form 10-K.
There
were no stock-based incentive grants during the three
months ended September 30, 2012. The following
table summarizes the Company’s stock option and
restricted stock award activity during the nine months
ended September 30, 2012:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 12 - Cash Dividends
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||
| Stockholders' Equity Note Disclosure [Text Block] |
12.
Cash Dividends
On
January 18, 2012, our board of directors declared that
the regular quarterly dividends to be paid to our
stockholders in 2012 will be $0.15 per share of
common stock, payable on March 14,
June 14, September 14 and December 14
of 2012 to stockholders of record on March 7,
June 7, September 7 and December 7 of 2012,
the record dates for each of the dividend payments,
respectively.
In
connection with the September 14, 2012, dividend payment,
the conversion rates for our convertible notes adjusted as
follows:
|
||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 13 - Income Taxes
|
9 Months Ended |
|---|---|
|
Sep. 30, 2012
|
|
| Income Tax Disclosure [Text Block] |
13.
Income Taxes
For
the three and nine months ended September 30, 2012 and
2011, income tax expense was primarily derived by applying
the federal statutory rate of 35% to operating income
before income taxes.
In
general, our income tax returns are subject to examination
by tax authorities for tax years 1995 forward. In May
2012, PDL received a “no-change” letter from
the Internal Revenue Service (IRS) upon completion of an
examination of the Company’s 2008 Federal tax return.
The California Franchise Tax Board (FTB) is currently
examining the Company’s 2008 and 2009 tax returns.
Although the timing of the resolution of income tax
examinations is highly uncertain, and the amounts
ultimately paid, if any, upon resolution of the issues
raised by the taxing authorities may differ materially from
the amounts accrued for each year, we do not anticipate any
material change to the amount of our unrecognized tax
benefits over the next 12 months.
|
| X | ||||||||||
|
- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 14 - Accumulated Other Comprehensive Income (Loss)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Comprehensive Income (Loss) Note [Text Block] |
14.
Accumulated Other Comprehensive Income (Loss)
Comprehensive
income comprises net income and other comprehensive income
(loss). We include unrealized net gains on investments held
in our available-for-sale securities and unrealized gains
(losses) on our cash flow hedges in other comprehensive
income (loss), and present the amounts net of tax. Our
other comprehensive income (loss) is included in our
Condensed Consolidated Statements of Comprehensive
Income.
The
balance of accumulated other comprehensive income (loss),
net of tax, was as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 15 - Subsequent Events
|
9 Months Ended |
|---|---|
|
Sep. 30, 2012
|
|
| Subsequent Events [Text Block] |
15.
Subsequent Events
Revenue
Interest Purchase Agreement
In
October 2012, PDL entered into a Revenue Interests Purchase
Agreement (Royalty Agreement) with AxoGen, Inc. (AxoGen),
pursuant to which PDL will receive specified royalties on
AxoGen’s Net Revenues (as defined in the Royalty
Agreement) generated by the sale, distribution or other use
of AxoGen’s products. The Royalty Agreement has an
eight year term, and provides PDL with high single digit
royalties based on AxoGen’s Net Revenues, subject to
agreed-upon minimum payments as provided by the Royalty
Agreement beginning in the fourth quarter of 2014, and the
right to require AxoGen to repurchase the revenue contract
at the end of the fourth year. AxoGen has been granted
certain rights to call the revenue contract in years five
through eight. The total consideration PDL paid to AxoGen
for the royalty rights was $20.8 million, including the
termination of an interim funding of $1.8 million in August
2012. AxoGen was required to use a portion of the proceeds
from the Royalty Agreement to pay the outstanding balance
under its existing credit facility. AxoGen plans to use the
remainder of the proceeds to support the business plan for
its products. The royalty rights are secured by the cash
and accounts receivable of AxoGen.
Credit
Agreement
In
November 2012, PDL loaned to Wellstat Diagnostics, LLC
(Wellstat) pursuant to a Credit Agreement (Credit
Agreement) $40 million to be used by Wellstat in
connection with its development and commercialization
of small point of care diagnostic systems that can
perform a wide variety of tests targeting the clinical
diagnostics market. Of the $40 million borrowed,
Wellstat Diagnostics will use approximately $11.6
million to repay an existing credit facility between
PDL and the holders of Wellstat’s equity
interests.
Outstanding
principal under the Credit Agreement bears interest at
the rate of 5.0% per annum, payable quarterly in
arrears, in cash or paid-in-kind notes that add to the
principal balance. The Credit Agreement
matures at its latest on December 31, 2021.
Wellstat is required to repay the outstanding principal
and a specific target internal rate of return amount to
PDL at maturity or upon the occurrence of certain key
events such as a sale of Wellstat Diagnostics or
substantially all of its assets or if Wellstat
Diagnostics misses a specified revenue target for
fiscal year 2017. The loan will be considered
repaid at any time the aggregate amount of all payments
made by Wellstat to PDL, including interest and any
royalty payments, equals specified target internal
rates of return set forth in the Credit
Agreement. The target internal rates of return
depend on whether the date of repayment is on or after
December 31, 2014, and is higher after December 31,
2014. Upon commercialization of Wellstat's diagnostic
systems, PDL will receive a low double digit royalty on
Wellstat Diagnostics' net
revenues.
The
Credit Agreement is secured by a pledge of
substantially all of the assets of Wellstat and a
pledge of all of Wellstat’s equity interests by
the holders thereof.
|
| X | ||||||||||
|
- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. No definition available.
|
|
Accounting Policies, by Policy (Policies)
|
9 Months Ended |
|---|---|
|
Sep. 30, 2012
|
|
| Basis of Accounting [Text Block] | Basis
of Presentation
The
accompanying unaudited Condensed Consolidated Financial
Statements have been prepared in accordance with U.S.
generally accepted accounting principles (GAAP) for interim
financial information. The financial statements include all
adjustments (consisting only of normal recurring
adjustments) the management of PDL BioPharma, Inc. (the
Company, PDL, we, us or our) believes are necessary for a
fair presentation of the periods presented. These interim
financial results are not necessarily indicative of results
expected for the full fiscal year or for any subsequent
interim period.
The
accompanying Condensed Consolidated Financial Statements
and related financial information should be read in
conjunction with the audited Consolidated Financial
Statements and the related notes thereto for the year ended
December 31, 2011, included in our Annual Report on Form
10-K filed with the U.S. Securities and Exchange
Commission. The Condensed Consolidated Balance Sheet at
December 31, 2011, has been derived from the audited
Consolidated Financial Statements at that date. |
| Consolidation, Policy [Policy Text Block] | Principles
of Consolidation
The
Consolidated Financial Statements include the accounts of
PDL and its wholly-owned subsidiaries. All material
intercompany balances and transactions have been eliminated
in consolidation. |
| Finance, Loans and Leases Receivable, Policy [Policy Text Block] | Notes
Receivable
We
account for our notes receivable at amortized cost, net of
unamortized origination fees, if any. Related
fees and costs are recorded net of amounts
reimbursed. Interest is accreted or accrued to
interest income using the interest method. |
| Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign
Currency Hedging
We
enter into foreign currency hedges to manage exposures
arising in the normal course of business and not for
speculative purposes.
We
hedge certain Euro-denominated currency exposures related
to our licensees’ product sales with Euro forward
contracts and, in 2011, Euro forward and option contracts.
In general, these contracts are intended to offset the
underlying Euro market risk in our royalty revenues. These
contracts extend through the fourth quarter of 2014. We
designate foreign currency exchange contracts used to hedge
royalty revenues based on underlying Euro-denominated sales
as cash flow hedges.
At
the inception of the hedging relationship and on a
quarterly basis, we assess hedge effectiveness. The fair
value of the Euro forward contracts is estimated using
pricing models with readily observable inputs from actively
quoted markets and is disclosed on a gross basis. The
aggregate unrealized gain or loss, net of tax, on the
effective portion of the hedge is recorded in
stockholders’ deficit as accumulated other
comprehensive income (loss). Gains or losses on cash flow
hedges are recognized as an adjustment to royalty revenue
in the same period that the hedged transaction impacts
earnings as royalty revenue. Any gain or loss on the
ineffective portions is reported in other income in the
period the ineffectiveness occurs.
During
the third quarter of 2012, we de-designated and terminated
a portion of our cash flow hedges. The gain realized was
reclassified from other comprehensive income (loss) to
other income in the third quarter. See Note 5 for
additional information on our foreign currency hedge
transactions. |
| Comprehensive Income, Policy [Policy Text Block] | Comprehensive
Income
In
the first quarter of 2012, we adopted Financial Accounting
Standards Board (FASB) accounting standard update (ASU)
2011-05, and have presented the components of other
comprehensive income (loss) in the Condensed Consolidated
Statements of Comprehensive Income. Also in accordance with
this ASU, we have applied this guidance retrospectively to
all periods presented. The adoption of the guidance was a
change to the presentation of other comprehensive income
(loss) and had no effect on our condensed consolidated
financial statements. See Note 14 for our discussion of
accumulated other comprehensive income (loss). |
| New Accounting Pronouncements, Policy [Policy Text Block] | Recent
Accounting Pronouncements
In
December 2011, the FASB issued ASU 2011-11 requiring new
disclosures associated with offsetting financial
instruments and derivative instruments on the balance sheet
that will enable users to evaluate the effect on an
entity’s financial position. The ASU will be
effective in the first quarter of 2013, but is not expected
to have a material impact on our financial
statements. |
| X | ||||||||||
|
- Definition
The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). No definition available.
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for comprehensive income. No definition available.
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for finance, loan and lease receivables, including those held for investment and those held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the allowance for loan and lease losses is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition (revenues, expenses and gains and losses arising from committing to issue, issuing, granting, collecting, terminating, modifying and holding loans) policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of the adoption of new accounting pronouncements that may impact the entity's financial reporting. No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. No definition available.
|
|
Note 2 - Net Income per Share (Tables)
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the numerators and the denominators of the basic and diluted per-share (or per-unit) computations for income from continuing operations, including the effect that has been given to preferred dividends. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 3 - Fair Value Measurements (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Liabilities Not Recorded At Fair Value [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 4 - Cash Equivalents, Short-term and Long-term Investments (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Available-for-sale Securities Reconciliation [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value, by Balance Sheet Grouping [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments Classified by Contractual Maturity Date [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments, assets, and liabilities. Such certain disclosures about the financial instruments, assets, and liabilities include: (1) the fair value of the required items together with their carrying amounts (as appropriate) and (2) the methodology and assumptions used in developing such estimates of fair value. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments. No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. No definition available.
|
|
Note 5 - Foreign Currency Hedging (Tables)
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Derivative Instruments [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 7 - Accrued Liabilities (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Accrued Liabilities [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the components of accrued liabilities. No definition available.
|
|
Note 9 - Convertible Notes and Non-recourse Notes (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Debt [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Series 2012 Notes [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule Of Interest Expense On Series 2012 Notes [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of notes including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of notes including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. No definition available.
|
|
Note 10 - Other Long-Term Liabilities (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Other Assets and Other Liabilities [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of other assets and other liabilities not separately disclosed on the balance sheet. No definition available.
|
|
Note 11 - Stock-Based Compensation (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 12 - Cash Dividends (Tables)
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||
| Schedule of Conversion Rates for Convertible Notes [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
|
Note 14 - Accumulated Other Comprehensive Income (Loss) (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the components of accumulated other comprehensive income (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 1 - Summary of Significant Accounting Policies (Detail) - Percentage of Total Revenue From Licenses Over 10% of Revenue
|
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
|
Genentech [Member] | Product Concentration Risk Avastin [Member]
|
||||
| Licensee | 30.00% | 28.00% | 31.00% | 30.00% |
|
Genentech [Member] | Product Concentration Risk Herceptin [Member]
|
||||
| Licensee | 36.00% | 38.00% | 35.00% | 34.00% |
|
Genentech [Member] | Product Concentration Risk Lucentis [Member]
|
||||
| Licensee | 15.00% | 15.00% | 18.00% | 16.00% |
|
Elan [Member] | Product Concentration Risk Tysabri [Member]
|
||||
| Licensee | 14.00% | 14.00% | 12.00% | 11.00% |
| X | ||||||||||
|
- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 2 - Net Income per Share (Detail) (USD $)
In Millions, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
|
Warrant [Member]
|
||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 19.2 | 17.5 | 19.2 | 17.5 |
|
Purchased Call Options [Member]
|
||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 22.6 | 20.6 | 22.6 | 20.6 |
|
Stock Options [Member]
|
||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 144,000.0 | 174,000.0 | 164,000.0 | 199,000.0 |
|
Due February 2015 [Member]
|
||||
| Debt Instrument, Interest Rate, Stated Percentage | 2.875% | 2.875% | ||
|
Series 2012 Notes [Member]
|
||||
| Debt Instrument, Interest Rate, Stated Percentage | 2.875% | 2.875% | ||
| Convertible Notes Payable (in Dollars) | $ 179.0 | $ 179.0 | ||
|
Convertible May 2015 Notes [Member]
|
||||
| Debt Instrument, Interest Rate, Stated Percentage | 3.75% | 3.75% | ||
|
Due 2012 [Member]
|
||||
| Debt Instrument, Interest Rate, Stated Percentage | 2.00% | 2.00% | ||
| X | ||||||||||
|
- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Interest rate stated in the contractual debt agreement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 2 - Net Income per Share (Detail) - Net Income Per Basic and Diluted Share (USD $)
In Thousands, except Per Share data, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Numerator | ||||
| Net income used to compute net income per basic share (in Dollars) | $ 48,575 | $ 45,916 | $ 162,261 | $ 160,447 |
| Add back interest expense for convertible notes, net of estimated tax of approximately $4,000 and $0.5 million for the three months ended September 30, 2012 and 2011, respectively and approximately $21,000 and $1.8 million for the nine months ended September 30, 2012 and 2011, respectively (see Note 9) (in Dollars) | 6 | 841 | 40 | 3,391 |
| Income used to compute net income per diluted share (in Dollars) | $ 48,581 | $ 46,757 | $ 162,301 | $ 163,838 |
| Denominator | ||||
| Total weighted-average shares used to compute net income per basic share | 139,715 | 139,680 | 139,693 | 139,665 |
| Weighted-average shares used to compute net income per diluted share | 149,626 | 167,019 | 150,678 | 186,756 |
| Net income per basic share (in Dollars per share) | $ 0.35 | $ 0.33 | $ 1.16 | $ 1.15 |
| Net income per diluted share (in Dollars per share) | $ 0.32 | $ 0.28 | $ 1.08 | $ 0.88 |
|
Restricted Stock [Member]
|
||||
| Denominator | ||||
| Restricted stock outstanding | 110 | 12 | 93 | 21 |
| Effect of dilutive stock options | 110 | 12 | 93 | 21 |
|
Stock Options [Member]
|
||||
| Denominator | ||||
| Restricted stock outstanding | 18 | 13 | 16 | 13 |
| Effect of dilutive stock options | 18 | 13 | 16 | 13 |
|
Series 2012 Notes [Member]
|
||||
| Denominator | ||||
| Assumed conversion of debt | 7,008 | 7,427 | ||
|
Convertible May 2015 Notes [Member]
|
||||
| Denominator | ||||
| Assumed conversion of debt | 2,609 | 2,825 | ||
|
Due February 2015 [Member]
|
||||
| Denominator | ||||
| Assumed conversion of debt | 166 | 27,314 | 624 | 27,314 |
|
Due 2012 [Member]
|
||||
| Denominator | ||||
| Assumed conversion of debt | 19,743 | |||
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The after-tax amount of interest recognized in the period associated with any convertible debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 2 - Net Income per Share (Detail) - Net Income Per Basic and Diluted Share (Parentheticals) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Estimated tax on interest expense for convertible notes (in Dollars) | $ 4 | $ 500 | $ 21 | $ 1,800 |
| X | ||||||||||
|
- Definition
The estimated tax on interest expense recognized in the period associated with any convertible debt. No definition available.
|
|
Note 3 - Fair Value Measurements (Detail) - Assets and Liabilities Recorded at Fair Value (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Financial assets: | ||
| Available for Sale Securities at Fair Value | $ 176,739 | $ 224,769 |
|
Derivative Financial Instruments, Liabilities [Member] | Fair Value, Inputs, Level 2 [Member]
|
||
| Financial liabilities: | ||
| Foreign currency hedge contracts | 4,446 | 9,783 |
|
Derivative Financial Instruments, Liabilities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Financial liabilities: | ||
| Foreign currency hedge contracts | 4,446 | 9,783 |
|
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
|
||
| Financial assets: | ||
| Available for Sale Securities at Fair Value | 128,962 | 163,368 |
|
Money Market Funds [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Financial assets: | ||
| Available for Sale Securities at Fair Value | 128,962 | 163,368 |
|
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]
|
||
| Financial assets: | ||
| Available for Sale Securities at Fair Value | 20,000 | |
|
Certificates of Deposit [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Financial assets: | ||
| Available for Sale Securities at Fair Value | 20,000 | |
|
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
|
||
| Financial assets: | ||
| Available for Sale Securities at Fair Value | 23,772 | 44,877 |
|
Corporate Debt Securities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Financial assets: | ||
| Available for Sale Securities at Fair Value | 23,772 | 44,877 |
|
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
|
||
| Financial assets: | ||
| Available for Sale Securities at Fair Value | 8,996 | |
|
Commercial Paper [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Financial assets: | ||
| Available for Sale Securities at Fair Value | 8,996 | |
|
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
|
||
| Financial assets: | ||
| Available for Sale Securities at Fair Value | 2,004 | 2,015 |
|
US Government Agencies Debt Securities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Financial assets: | ||
| Available for Sale Securities at Fair Value | 2,004 | 2,015 |
|
US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]
|
||
| Financial assets: | ||
| Available for Sale Securities at Fair Value | 2,001 | 5,513 |
|
US Treasury Securities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Financial assets: | ||
| Available for Sale Securities at Fair Value | 2,001 | 5,513 |
|
Derivative Financial Instruments, Assets [Member] | Fair Value, Inputs, Level 2 [Member]
|
||
| Financial assets: | ||
| Foreign currency hedge contracts | 562 | 6,838 |
|
Derivative Financial Instruments, Assets [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Financial assets: | ||
| Foreign currency hedge contracts | 562 | 6,838 |
|
Fair Value, Inputs, Level 1 [Member]
|
||
| Financial assets: | ||
| Total | 132,967 | 170,896 |
|
Fair Value, Inputs, Level 2 [Member]
|
||
| Financial assets: | ||
| Total | 44,334 | 60,711 |
|
Estimate of Fair Value, Fair Value Disclosure [Member]
|
||
| Financial assets: | ||
| Total | $ 177,301 | $ 231,607 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents contracts related to the exchange of different currencies, including foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into and existing as of the balance sheet date. No definition available.
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents contracts related to the exchange of different currencies, including foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into and existing as of the balance sheet date. No definition available.
|
|
Note 3 - Fair Value Measurements (Detail) - Assets and Liabilities Not Recorded at Fair Value (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Assets: | ||
| Notes receivable carrying value | $ 46,672 | |
| Liabilities: | ||
| Notes payable carrying value | 307,337 | 409,985 |
|
Merus Labs Note Receivable [Member] | Fair Value, Inputs, Level 2 [Member]
|
||
| Assets: | ||
| Notes receivable fair value | 34,999 | |
|
Merus Labs Note Receivable [Member]
|
||
| Assets: | ||
| Notes receivable carrying value | 35,000 | |
|
Senior Secured Note Receivable [Member] | Fair Value, Inputs, Level 2 [Member]
|
||
| Assets: | ||
| Notes receivable fair value | 9,813 | |
|
Senior Secured Note Receivable [Member]
|
||
| Assets: | ||
| Notes receivable carrying value | 9,922 | |
|
Other Notes Receivable [Member] | Fair Value, Inputs, Level 3 [Member]
|
||
| Assets: | ||
| Notes receivable fair value | 1,750 | |
|
Other Notes Receivable [Member]
|
||
| Assets: | ||
| Notes receivable carrying value | 1,750 | |
|
Fair Value, Inputs, Level 2 [Member] | Series 2012 Notes [Member]
|
||
| Liabilities: | ||
| Notes payable fair value | 239,413 | |
|
Fair Value, Inputs, Level 2 [Member] | Convertible May 2015 Notes [Member]
|
||
| Liabilities: | ||
| Notes payable fair value | 191,152 | 156,123 |
|
Fair Value, Inputs, Level 2 [Member] | Convertible February 2015 Notes [Member]
|
||
| Liabilities: | ||
| Notes payable fair value | 1,338 | 191,475 |
|
Fair Value, Inputs, Level 2 [Member] | Non-Recourse Notes [Member]
|
||
| Liabilities: | ||
| Notes payable fair value | 95,237 | |
|
Fair Value, Inputs, Level 2 [Member]
|
||
| Assets: | ||
| Notes receivable fair value | 44,812 | |
| Liabilities: | ||
| Notes payable fair value | 431,903 | 442,835 |
|
Fair Value, Inputs, Level 3 [Member]
|
||
| Assets: | ||
| Notes receivable fair value | 1,750 | |
|
Series 2012 Notes [Member]
|
||
| Liabilities: | ||
| Notes payable carrying value | 164,065 | |
|
Convertible May 2015 Notes [Member]
|
||
| Liabilities: | ||
| Notes payable carrying value | 142,282 | 138,952 |
|
Convertible February 2015 Notes [Member]
|
||
| Liabilities: | ||
| Notes payable carrying value | 990 | 177,663 |
|
Non-Recourse Notes [Member]
|
||
| Liabilities: | ||
| Notes payable carrying value | $ 93,370 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. No definition available.
|
| X | ||||||||||
|
- Definition
An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) more than one year from the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. An amount representing an agreement for an unconditional promise by the maker to pay the Company (holder) a definite sum of money at a future date(s). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 4 - Cash Equivalents, Short-term and Long-term Investments (Detail) (USD $)
|
3 Months Ended | 9 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Dec. 31, 2011
|
|
| Available-for-sale Securities, Gross Realized Gain (Loss) | $ 11,000 | $ 0 | $ 11,000 | $ 0 | |
| Other than Temporary Impairment Losses, Investments, Available-for-sale Securities | $ 0 | $ 0 | |||
| X | ||||||||||
|
- Definition
This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 4 - Cash Equivalents, Short-term and Long-term Investments (Detail) - Available-for-Sale Debt Securities (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Amortized Cost | $ 176,697 | $ 224,725 |
| Gross Unrealized Gains | 42 | 88 |
| Gross Unrealized Losses | (44) | |
| Estimated Fair Value | 176,739 | 224,769 |
|
Money Market Funds [Member]
|
||
| Amortized Cost | 128,962 | 163,368 |
| Gross Unrealized Gains | 0 | 0 |
| Gross Unrealized Losses | 0 | 0 |
| Estimated Fair Value | 128,962 | 163,368 |
|
Certificates of Deposit [Member]
|
||
| Amortized Cost | 20,000 | |
| Gross Unrealized Gains | 0 | |
| Gross Unrealized Losses | 0 | |
| Estimated Fair Value | 20,000 | |
|
Corporate Debt Securities [Member]
|
||
| Amortized Cost | 23,735 | 44,863 |
| Gross Unrealized Gains | 37 | 57 |
| Gross Unrealized Losses | 0 | (43) |
| Estimated Fair Value | 23,772 | 44,877 |
|
US Government Agencies Debt Securities [Member]
|
||
| Amortized Cost | 2,001 | 2,003 |
| Gross Unrealized Gains | 3 | 12 |
| Gross Unrealized Losses | 0 | 0 |
| Estimated Fair Value | 2,004 | 2,015 |
|
US Treasury Securities [Member]
|
||
| Amortized Cost | 1,999 | 5,494 |
| Gross Unrealized Gains | 2 | 19 |
| Gross Unrealized Losses | 0 | 0 |
| Estimated Fair Value | 2,001 | 5,513 |
|
Commercial Paper [Member]
|
||
| Amortized Cost | 8,997 | |
| Gross Unrealized Gains | 0 | |
| Gross Unrealized Losses | (1) | |
| Estimated Fair Value | $ 8,996 |
| X | ||||||||||
|
- Definition
This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents the gross unrealized gains for securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents the gross unrealized losses for securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities. No definition available.
|
|
Note 4 - Cash Equivalents, Short-term and Long-term Investments (Detail) - Available-For-Sale Securities Balance Sheet Classification (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Cash equivalents | $ 128,962 | $ 165,367 |
| Restricted investment | 20,000 | |
| Short-term investments | 27,777 | 42,301 |
| Long-term investments | 17,101 | |
| Total | $ 176,739 | $ 224,769 |
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Company may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 4 - Cash Equivalents, Short-term and Long-term Investments (Detail) - Summary of Available-For-Sale Securities (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Less than one year | $ 176,697 | $ 207,630 |
| Less than one year | 176,739 | 207,668 |
| Greater than one year but less than five years | 17,095 | |
| Greater than one year but less than five years | 17,101 | |
| Total | 176,697 | 224,725 |
| Total | $ 176,739 | $ 224,769 |
| X | ||||||||||
|
- Definition
Amount of available-for-sale debt securities at cost, net of adjustments, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings (less any cumulative-effect adjustments, as defined) and fair value hedge accounting adjustments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of available-for-sale debt securities at fair value maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of available-for-sale debt securities at cost, net of adjustments, which include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings (less any cumulative-effect adjustments, as defined) and fair value hedge accounting adjustments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of available-for-sale debt securities at cost, net of adjustments, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings (less any cumulative-effect adjustments, as defined) and fair value hedge accounting adjustments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of available-for-sale debt securities at fair value maturing in the next fiscal year following the latest fiscal year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of debt securities categorized neither as held-to-maturity nor trading. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 5 - Foreign Currency Hedging (Detail) (Net of Tax [Member], USD $)
In Millions, unless otherwise specified |
3 Months Ended |
|---|---|
|
Sep. 30, 2012
|
|
|
Net of Tax [Member]
|
|
| Gain on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring | $ 391,000 |
| X | ||||||||||
|
- Definition
The amount of gain reclassified into earnings in the period when cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 5 - Foreign Currency Hedging (Detail) - Foreign Currency Exchange Contracts Designated as Cash Flow Hedges (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
|
Eurodollar Sell Forward Contract 1.400 [Member] | Contracts In Place December 31, 2011 [Member] | Foreign Exchange Forward [Member]
|
||
| Settlement Price ($ per Eurodollar) | 1.400 | |
| Notional Amount | $ 25,150 | |
| Fair Value | 1,837 | |
| Notional Amount | 25,150 | |
| Fair Value | 1,837 | |
|
Eurodollar Sell Forward Contract 1.200 [Member] | Contracts In Place December 31, 2011 [Member] | Foreign Exchange Forward [Member]
|
||
| Settlement Price ($ per Eurodollar) | 1.200 | |
| Notional Amount | 117,941 | |
| Fair Value | (9,783) | |
| Notional Amount | 117,941 | |
| Fair Value | (9,783) | |
|
Eurodollar Sell Foward Contract 1.230 [Member] | Foreign Exchange Forward [Member]
|
||
| Settlement Price ($ per Eurodollar) | 1.230 | |
| Notional Amount | 55,246 | |
| Fair Value | (2,636) | |
| Notional Amount | 55,246 | |
| Fair Value | (2,636) | |
|
Eurodollar Sell Forward Contract 1.240 [Member] | Foreign Exchange Forward [Member]
|
||
| Settlement Price ($ per Eurodollar) | 1.240 | |
| Notional Amount | 10,850 | |
| Fair Value | (462) | |
| Notional Amount | 10,850 | |
| Fair Value | (462) | |
|
Eurodollar Sell Forward Contract 1.270 [Member] | Foreign Exchange Forward [Member]
|
||
| Settlement Price ($ per Eurodollar) | 1.270 | |
| Notional Amount | 44,450 | |
| Fair Value | (890) | |
| Notional Amount | 44,450 | |
| Fair Value | (890) | |
|
Eurodollar Sell Forward Exchange 1.281 [Member] | Foreign Exchange Forward [Member]
|
||
| Settlement Price ($ per Eurodollar) | 1.281 | |
| Notional Amount | 36,814 | |
| Fair Value | (458) | |
| Notional Amount | 36,814 | |
| Fair Value | (458) | |
|
Eurodollar Sell Foward Contract 1.300 [Member] | Foreign Exchange Forward [Member]
|
||
| Settlement Price ($ per Eurodollar) | 1.300 | |
| Notional Amount | 91,000 | |
| Fair Value | 562 | |
| Notional Amount | 91,000 | |
| Fair Value | 562 | |
|
Eurodollar Purchased Call Option 1.510 [Member] | Contracts In Place December 31, 2011 [Member] | Foreign Exchange Option [Member]
|
||
| Notional Amount | 27,126 | |
| Strike Price ($ per Eurodollar) (in Dollars per Item) | 1.510 | |
| Notional Amount | 27,126 | |
|
Eurodollar Purchased Call Option 1.315 [Member] | Contracts In Place December 31, 2011 [Member] | Foreign Exchange Option [Member]
|
||
| Notional Amount | 129,244 | |
| Fair Value | 5,001 | |
| Strike Price ($ per Eurodollar) (in Dollars per Item) | 1.315 | |
| Notional Amount | 129,244 | |
| Fair Value | 5,001 | |
|
Contracts In Place December 31, 2011 [Member] | Foreign Exchange Option [Member]
|
||
| Notional Amount | 156,370 | |
| Fair Value | 5,001 | |
| Notional Amount | 156,370 | |
| Fair Value | 5,001 | |
|
Foreign Exchange Forward [Member]
|
||
| Notional Amount | 238,360 | 143,091 |
| Fair Value | (3,884) | (7,946) |
| Notional Amount | 238,360 | 143,091 |
| Fair Value | $ (3,884) | $ (7,946) |
| X | ||||||||||
|
- Definition
The strike price on the foreign currency option contract such as a put option or a call option. No definition available.
|
| X | ||||||||||
|
- Definition
Contractual rate at which a foreign currency can be purchased or sold. No definition available.
|
| X | ||||||||||
|
- Definition
Fair value as of the balance sheet date of all foreign currency derivatives designated as cash flow hedging instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate notional amount of all foreign currency derivatives designated as hedging instruments in cash flow hedges. Notional amount refers to the number of currency units specified in the foreign currency derivative contract. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 5 - Foreign Currency Hedging (Detail) - Fair Value of Foreign Currency Exchange Contracts on Condensed Consolidated Balance Sheet (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
|
Prepaid And Other Current Assets [Member]
|
||
| Euro contracts | $ 476 | $ 1,837 |
|
Other Assets [Member]
|
||
| Euro contracts | 86 | |
|
Accrued Liabilities [Member]
|
||
| Euro contracts | 2,636 | 4,134 |
|
Other Long-Term Liabilities [Member]
|
||
| Euro contracts | $ 1,810 | $ 648 |
| X | ||||||||||
|
- Definition
Fair values as of the balance sheet date for all assets resulting from contracts that meet the criteria of being accounted for as derivative instruments and which are expected to be converted into cash or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Fair values as of the balance sheet date of all assets resulting from contracts that meet the criteria of being accounted for as derivative instruments which are expected to exist longer than one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of after one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 5 - Foreign Currency Hedging (Detail) - Derivative Instruments Designated as Cash Flow Hedges Effect on Other Comprehensive Income (Loss) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|||||||||||||
| Net gain (loss) recognized in OCI, net of tax (1) | $ (3,454) | [1] | $ 3,841 | [1] | $ (1,851) | [1] | $ (4,835) | [1] | ||||||||
| Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax (2) | (328) | [2] | (440) | [2] | (998) | [2] | 146 | [2] | ||||||||
| Amount excluded from effectiveness testing | 0 | 0 | 0 | 0 | ||||||||||||
|
Cash Flow Hedges [Member]
|
||||||||||||||||
| Net loss recognized in interest and other income, net -- cash flow hedges (3) | (27) | [3] | [3] | (54) | [3] | (19) | [3] | |||||||||
| Net gain recognized in interest and other income, net -- non-designated contracts (4) | (27) | [3] | [3] | (54) | [3] | (19) | [3] | |||||||||
|
Non-designated Contracts [Member]
|
||||||||||||||||
| Net loss recognized in interest and other income, net -- cash flow hedges (3) | 391 | [4] | [4] | 391 | [4] | [4] | ||||||||||
| Net gain recognized in interest and other income, net -- non-designated contracts (4) | $ 391 | [4] | [4] | $ 391 | [4] | [4] | ||||||||||
|
||||||||||||||||
| X | ||||||||||
|
- Definition
The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net gains and losses recognized in income during the period on derivative instruments designated and qualifying as hedging instruments in fair value hedges and related hedged items designated and qualifying in fair value hedges, on derivative instruments designated and qualifying as hedging instruments in cash flow hedges, and on derivative instruments not designated as hedging instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The effective portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments that was recognized in other comprehensive income during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 6 - Notes and Other Long-term Receivables (Detail) (USD $)
In Millions, unless otherwise specified |
9 Months Ended | 3 Months Ended | |||||
|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2012
Initial Loan [Member]
Merus Labs International Inc. [Member]
|
Sep. 30, 2012
Additional Loan [Member]
Merus Labs International Inc. [Member]
|
Aug. 31, 2012
Senior Secured Note Receivable [Member]
|
Mar. 31, 2012
Senior Secured Note Receivable [Member]
|
Sep. 30, 2012
Merus Labs International Inc. [Member]
|
Sep. 30, 2012
Merus Labs International Inc. [Member]
|
|
| Increase (Decrease) in Finance Receivables | $ 35.0 | ||||||
| Letter of Credit Extended | 20.0 | ||||||
| Business Acquisition, Cost of Acquired Entity, Liabilities Incurred | 20.0 | ||||||
| Interest Rate on Note Receivable | 13.50% | 14.00% | 12.00% | 10.00% | |||
| Financing Receivable Future Principal Payments in Current Fiscal Year | 5.0 | ||||||
| Financing Receivable Future Principal Payments in Two Years | 7.5 | ||||||
| Financing Receivable Future Principal Payments in Three Years | 10.0 | ||||||
| Financing Receivable Future Principal Payments In Four Years | 12.5 | ||||||
| Financing Receivable, Gross | $ 10.0 | $ 7.5 | |||||
| X | ||||||||||
|
- Definition
Financing receivable future principal payments in current fiscal year. No definition available.
|
| X | ||||||||||
|
- Definition
Financing receivable future principal payments in four years. No definition available.
|
| X | ||||||||||
|
- Definition
Financing receivable future principal payments in three years. No definition available.
|
| X | ||||||||||
|
- Definition
Financing receivable future principal payments in two years. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Letter of credit extended. No definition available.
|
| X | ||||||||||
|
- Definition
Fair Value of the liabilities incurred by the acquirer to former owners of the acquiree, including the fair value of any contingent consideration. If liabilities transferred as consideration remain within the combined entity after the business combination (for example, because the assets or liabilities were transferred to the acquiree rather than to its former owners), and the acquirer therefore retains control of them; in that situation, the acquirer measures those liabilities at their carrying amounts immediately before the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in outstanding loans including accrued interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount representing an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. Excludes amounts related to receivables held-for-sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 7 - Accrued Liabilities (Detail) - Accrued Liabilities (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Compensation | $ 1,872 | $ 1,341 |
| Interest payable | 3,087 | 3,351 |
| Deferred revenue | 1,713 | |
| Foreign currency hedge | 2,636 | 4,134 |
| Dividend payable | 21,109 | 52 |
| Other | 2,779 | 1,018 |
| Total | $ 31,483 | $ 11,609 |
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 8 - Commitments and Contingencies (Detail) (USD $)
In Millions, unless otherwise specified |
9 Months Ended | |||||
|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
Dec. 31, 2011
|
Jul. 07, 2011
|
Sep. 30, 2012
Past U.S. Based Sales [Member]
|
Sep. 30, 2012
Future U.S. Based Sales [Member]
|
Sep. 30, 2012
Europe [Member]
|
|
| RoyaltyRevenueGeographicConcentration | 35.00% | |||||
| Royalty Rate | 3.75% | 3.75% | ||||
| Number of Genentech's Claims Dismissed by Court | 2 | |||||
| Number of PDL's Claims Upheld by Court | 4 | |||||
| Number of PDL's claims for relief relating to the 2003 settlement agreement | 5 | |||||
| Number of PDL's claims dismissed by the court | 1 | |||||
| Operating Leases, Future Minimum Payments Due (in Dollars) | $ 103.0 | |||||
| Loss Contingency, Estimate of Possible Loss (in Dollars) | $ 10.7 | $ 10.7 | ||||
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Number of PDL's claims dismissed by the court No definition available.
|
| X | ||||||||||
|
- Definition
Number of PDL's claims for relief relating to the 2003 settlement agreement. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Retroactive royalty rate on past US-based Sales of the Genentech Products and interest, among other items. No definition available.
|
| X | ||||||||||
|
- Definition
Revenues derived from sales of products that were made in US and foreign geographies. No definition available.
|
| X | ||||||||||
|
- Definition
Reflects the estimated amount of loss from the specified contingency as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 9 - Convertible Notes and Non-recourse Notes (Detail) (USD $)
Share data in Millions, except Per Share data, unless otherwise specified |
6 Months Ended | 9 Months Ended | 9 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 9 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2012
|
Sep. 30, 2012
|
Sep. 30, 2012
February 2015 Notes Exchanged For Series 2012 Notes [Member]
Convertible February 2015 Notes [Member]
|
Sep. 30, 2012
Initial [Member]
Series 2012 Notes [Member]
|
Sep. 30, 2012
Minimum [Member]
Series 2012 Notes [Member]
|
Jun. 30, 2012
Minimum [Member]
Series 2012 Notes [Member]
|
Sep. 30, 2012
Minimum [Member]
Convertible May 2015 Notes [Member]
|
Jun. 30, 2012
Minimum [Member]
Convertible May 2015 Notes [Member]
|
Feb. 29, 2012
Series 2012 Notes [Member]
|
Mar. 31, 2012
Series 2012 Notes [Member]
|
Sep. 30, 2012
Series 2012 Notes [Member]
|
Dec. 31, 2011
Series 2012 Notes [Member]
|
Jan. 31, 2012
Series 2012 Notes [Member]
|
Sep. 30, 2012
Convertible February 2015 Notes [Member]
|
Jan. 31, 2012
Convertible February 2015 Notes [Member]
|
Sep. 30, 2012
February 2015 Notes Exchanged For Series 2012 Notes [Member]
|
Sep. 30, 2012
Convertible May 2015 Notes [Member]
|
Dec. 31, 2011
Convertible May 2015 Notes [Member]
|
|
| Convertible Debt | $ 169,000,000 | $ 1,000,000 | $ 1,000,000 | |||||||||||||||
| Incentive Fee Per Thousand to Convert Debt | 5.00 | |||||||||||||||||
| Induced Conversion of Convertible Debt Expense | 845,000 | |||||||||||||||||
| Deferred Costs, Noncurrent | 765,000 | |||||||||||||||||
| Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt | 52,000 | 10,900,000 | ||||||||||||||||
| Noted Obligation Allocated To Deferred Tax Asset | 28,000 | |||||||||||||||||
| Debt Conversion, Converted Instrument, Amount | 10,000,000 | |||||||||||||||||
| Debt Instrument, Interest Rate, Stated Percentage | 2.875% | 2.875% | 3.75% | |||||||||||||||
| Debt Instrument, Convertible, Conversion Ratio | 155.3960 | 166.2640 | 166.2640 | 145.4893 | ||||||||||||||
| Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 6.44 | $ 7.82 | $ 7.98 | $ 8.94 | $ 9.12 | $ 6.01 | $ 6.01 | $ 6.87 | ||||||||||
| Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction | 216,000 | 813,000 | 597,000 | |||||||||||||||
| Debt Instrument, Convertible, Terms of Conversion Feature | During any fiscal quarter commencing after the fiscal quarter ending December 31, 2011, if the closing price of the Company's common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price for the Series 2012 Notes on the last day of such preceding fiscal quarter; During the five business-day period immediately after any five consecutive trading-day period in which the trading price per $1,000 principal amount of the Series 2012 Notes for each trading day of that measurement period was less than 98% of the product of the closing price of the Company's common stock and the conversion rate for the Series 2012 Notes for that trading day; Upon the occurrence of certain corporate transactions as provided in the Indenture; or Anytime, at the holder's option, beginning on August 15, 2014. | |||||||||||||||||
| Debt Instrument, Unamortized Discount | 2,300,000 | 14,935,000 | 10,000 | 16,800,000 | 12,968,000 | 16,298,000 | ||||||||||||
| Debt Instrument, Convertible, Effective Interest Rate | 7.30% | |||||||||||||||||
| Noted obligation allocated to deferred tax liability | 5,900,000 | |||||||||||||||||
| Debt Instrument, Convertible, Remaining Discount Amortization Period | 2 years 146 days | 2 years 146 days | 2 years 219 days | |||||||||||||||
| Debt Instrument, Fair Value Disclosure | 50,200,000 | |||||||||||||||||
| Amount by Which Fair Value Exceeds Face Value | 18,700,000 | |||||||||||||||||
| Option Indexed to Issuer's Equity, Shares (in Shares) | 22.6 | |||||||||||||||||
| Option Indexed to Issuer's Equity, Strike Price (in Dollars per Item) | 6.87 | |||||||||||||||||
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 27.5 | |||||||||||||||||
| Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item) | 8.09 | |||||||||||||||||
| Unamortized Debt Issuance Expense | $ 14,000 |
| X | ||||||||||
|
- Definition
Amount by which fair value exceeds face value. No definition available.
|
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Adjustment to deferred tax asset resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. No definition available.
|
| X | ||||||||||
|
- Definition
Adjustment to deferred tax liability resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. No definition available.
|
| X | ||||||||||
|
- Definition
Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The exercise price of each class of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The specified number of securities that each class of warrants or rights outstanding give the holder the right but not the obligation to purchase from the issuer at a specific price, on or before a certain date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The price per share of the conversion feature embedded in the debt instrument. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The ratio applied to the debt for purposes of determining the number of shares of the equity security into which the debt will be converted. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The effective interest rate on the liability component of convertible debt instrument which may be settled in cash upon conversion, including partial cash settlement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Interest rate stated in the contractual debt agreement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of shares that could be issued to net share settle a contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that may be required to be issued, disclose the fact that a potentially infinite number of shares could be issued to settle the contract. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The exercise (or strike) price stated in the contract. The fixed price at which the option holder can purchase, in the case of a call option, or sell, in the case of a put option, on the underlying security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 9 - Convertible Notes and Non-recourse Notes (Detail) - Convertible and Non-recourse Notes Activity (USD $)
In Thousands, unless otherwise specified |
9 Months Ended | |
|---|---|---|
|
Sep. 30, 2012
|
Dec. 31, 2011
|
|
| Convertible Notes | ||
| Carrying Value | $ 307,337 | $ 409,985 |
|
Series 2012 Notes [Member]
|
||
| Convertible Notes | ||
| Maturity Date | Feb. 15, 2015 | |
| Principal Balance Outstanding | 179,000 | |
| Carrying Value | 164,065 | |
|
Convertible May 2015 Notes [Member]
|
||
| Convertible Notes | ||
| Maturity Date | May 01, 2015 | |
| Principal Balance Outstanding | 155,250 | 155,250 |
| Carrying Value | 142,282 | 138,952 |
|
Convertible February 2015 Notes [Member]
|
||
| Convertible Notes | ||
| Maturity Date | Feb. 15, 2015 | |
| Principal Balance Outstanding | 1,000 | |
| Carrying Value | 990 | 177,663 |
|
Non-Recourse Notes [Member]
|
||
| Convertible Notes | ||
| Maturity Date | Sep. 15, 2012 | |
| Carrying Value | $ 93,370 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The stated principal amount of the debt instrument at time of issuance, which may vary from the carrying amount because of unamortized premium or discount. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 9 - Convertible Notes and Non-recourse Notes (Detail) - Series 2012 Notes (USD $)
|
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Net carrying value of the Series 2012 Notes | $ 307,337,000 | $ 409,985,000 |
|
Series 2012 Notes [Member]
|
||
| Principal amount of the Series 2012 Notes | 179,000,000 | |
| Unamortized discount of liability component | (14,935,000) | |
| Net carrying value of the Series 2012 Notes | $ 164,065,000 |
| X | ||||||||||
|
- Definition
The stated principal amount of the debt instrument at time of issuance, which may vary from the carrying amount because of unamortized premium or discount. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 9 - Convertible Notes and Non-recourse Notes (Detail) - Interest Expense For Our Series 2012 Notes (Series 2012 Notes [Member], USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended |
|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2012
|
|
|
Series 2012 Notes [Member]
|
||
| Contractual coupon interest | $ 1,287 | $ 3,836 |
| Amortization of debt issuance costs | 279 | 826 |
| Amortization of debt discount | 1,439 | 4,219 |
| Total | $ 3,005 | $ 8,881 |
| X | ||||||||||
|
- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Interest expense related to convertible debt instruments which has been recognized for the period, including the contractual interest coupon and amortization of the debt discount, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 9 - Convertible Notes and Non-recourse Notes (Detail) - May 2015 Notes (USD $)
|
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Net carrying value of the May 2015 Notes | $ 307,337,000 | $ 409,985,000 |
|
Convertible May 2015 Notes [Member]
|
||
| Principal amount of the May 2015 Notes | 155,250,000 | 155,250,000 |
| Unamortized discount of liability component | (12,968,000) | (16,298,000) |
| Net carrying value of the May 2015 Notes | $ 142,282,000 | $ 138,952,000 |
| X | ||||||||||
|
- Definition
The stated principal amount of the debt instrument at time of issuance, which may vary from the carrying amount because of unamortized premium or discount. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 9 - Convertible Notes and Non-recourse Notes (Detail) - Interest Expense for our May 2015 Notes (Convertible May 2015 Notes [Member], USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
|
Convertible May 2015 Notes [Member]
|
||||
| Contractual coupon interest | $ 1,455 | $ 1,455 | $ 4,366 | $ 2,183 |
| Amortization of debt issuance costs | 299 | 290 | 891 | 434 |
| Amortization of debt discount | 1,130 | 1,051 | 3,330 | 1,570 |
| Total | $ 2,884 | $ 2,796 | $ 8,587 | $ 4,187 |
| X | ||||||||||
|
- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Interest expense related to convertible debt instruments which has been recognized for the period, including the contractual interest coupon and amortization of the debt discount, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 10 - Other Long-Term Liabilities (Detail) - Other Long-term Liabilities (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
|---|---|---|
| Accrued lease liability | $ 10,700 | $ 10,700 |
| Uncertain tax position | 12,858 | 12,774 |
| Compensation | 379 | |
| Foreign currency hedge | 1,810 | 648 |
| Total | $ 25,747 | $ 24,122 |
| X | ||||||||||
|
- Definition
Employee related liabilities noncurrent. No definition available.
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for contractual rent under lease arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Fair value of derivative liability, presented on a gross basis even when the derivative instrument is subject to master netting arrangements and qualifies for net presentation in the statement of financial position. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The noncurrent portion of the amount recognized for uncertain tax positions as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 11 - Stock-Based Compensation (Detail) - Stock Option and Restricted Stock Award Activity (USD $)
In Thousands, except Per Share data, unless otherwise specified |
9 Months Ended |
|---|---|
|
Sep. 30, 2012
|
|
| Balance December 31, 2011 | 4,710 |
| Granted | (117) |
| Forfeited or cancelled | 2 |
| Balance at September 30, 2012 | 4,595 |
|
Stock Options [Member]
|
|
| Balance December 31, 2011 | 231 |
| Balance December 31, 2011 (in Dollars per share) | $ 16.62 |
| Forfeited or cancelled | (35) |
| Forfeited or cancelled (in Dollars per share) | $ 18.83 |
| Balance at September 30, 2012 | 196 |
| Balance at September 30, 2012 (in Dollars per share) | $ 16.22 |
|
Restricted Stock [Member]
|
|
| Balance December 31, 2011 | 137 |
| Balance December 31, 2011 (in Dollars per share) | $ 6.09 |
| Granted | 117 |
| Granted (in Dollars per share) | $ 6.30 |
| Shares released | (44) |
| Shares released (in Dollars per share) | $ 6.73 |
| Forfeited or cancelled | (2) |
| Forfeited or cancelled (in Dollars per share) | $ 6.22 |
| Balance at September 30, 2012 | 208 |
| Balance at September 30, 2012 (in Dollars per share) | $ 6.26 |
| X | ||||||||||
|
- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net number of non-option equity instruments granted to participants. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. No definition available.
|
|
Note 12 - Cash Dividends (Detail) (USD $)
|
Sep. 30, 2012
|
Jan. 18, 2012
|
|---|---|---|
| Dividends Payable, Amount Per Share (in Dollars per share) | $ 0.15 | |
| Dividends Payable Dates To be Paid Day Month And Year | March14, June14,September14 and December14 of 2012 | |
| Dividends Payable Dates of Record, Day, Month and Year | March7, June7,September7 and December 7 of 2012 |
| X | ||||||||||
|
- Definition
Declaration of date(s) as of when a holder must own the stock to be entitled to the dividend. The ex-dividend date is generally 3 days before the record date. No definition available.
|
| X | ||||||||||
|
- Definition
For declared dividends, day, month, and year (YYYY-MM-DD) that the dividend declared as of or prior to the financial reporting date will be paid in the subsequent period. No definition available.
|
| X | ||||||||||
|
- Definition
The per share amount of a dividend declared, but not paid, as of the financial reporting date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 12 - Cash Dividends (Detail) - Conversion Rates for Convertible Notes (USD $)
|
9 Months Ended |
|---|---|
|
Sep. 30, 2012
|
|
|
Series 2012 Notes [Member]
|
|
| Conversion Rate per $1,000 Principal Amount | 166.264 |
| Approximate Conversion Price Per Common Share (in Dollars per share) | $ 6.01 |
| Effective Date | Sep. 05, 2012 |
|
Convertible May 2015 Notes [Member]
|
|
| Conversion Rate per $1,000 Principal Amount | 145.4893 |
| Approximate Conversion Price Per Common Share (in Dollars per share) | $ 6.87 |
| Effective Date | Sep. 05, 2012 |
|
Convertible February 2015 Notes [Member]
|
|
| Conversion Rate per $1,000 Principal Amount | 166.264 |
| Approximate Conversion Price Per Common Share (in Dollars per share) | $ 6.01 |
| Effective Date | Sep. 10, 2012 |
| X | ||||||||||
|
- Definition
The price per share of the conversion feature embedded in the debt instrument. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The ratio applied to the debt for purposes of determining the number of shares of the equity security into which the debt will be converted. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Earliest date when the debt instrument can be converted into equity, in CCYY-MM-DD format. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 13 - Income Taxes (Detail)
|
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate | 35.00% | 35.00% | 35.00% | 35.00% |
| X | ||||||||||
|
- Definition
The domestic federal statutory tax rate applicable under enacted tax laws to the Company's pretax income from continuing operations for the period. The "statutory" tax rate is the regular tax rate if there are alternative tax systems. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 14 - Accumulated Other Comprehensive Income (Loss) (Detail) - Accumulated Other Comprehensive Income (Loss), Net of Tax (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Beginning Balance at December 31, 2011 | $ 29 | |||
| Beginning Balance at December 31, 2011 | (1,914) | |||
| Beginning Balance at December 31, 2011 | (1,885) | |||
| Activity for the nine months ended September 30, 2012 | (14) | (55) | (1) | (8) |
| Activity for the nine months ended September 30, 2012 | (3,126) | 4,281 | (853) | (4,981) |
| Activity for the nine months ended September 30, 2012 | (3,140) | 4,226 | (854) | (4,989) |
| Ending Balance at September 30, 2012 | 28 | 28 | ||
| Ending Balance at September 30, 2012 | (2,767) | (2,767) | ||
| Ending Balance at September 30, 2012 | $ (2,739) | $ (2,739) | ||
| X | ||||||||||
|
- Definition
Accumulated appreciation or loss, net of tax, in value of the total of available-for-sale securities at the end of an accounting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Accumulated change, net of tax, in accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges. Includes an entity's share of an equity investee's Increase or Decrease in deferred hedging gains or losses. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net of tax amount of other comprehensive income (loss) attributable to both parent entity and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net of tax amount, before reclassification adjustments, of the change in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges. Also includes an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net of tax amount of unrealized holding gain (loss) before reclassification adjustments and transfers on available-for-sale securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Note 15 - Subsequent Events (Detail) (Subsequent Event [Member], USD $)
In Millions, unless otherwise specified |
9 Months Ended | 3 Months Ended | 9 Months Ended | |
|---|---|---|---|---|
|
Sep. 30, 2012
AxoGen Inc. [Member]
|
Sep. 30, 2012
Wellstat Diagnostics LLC [Member]
|
Sep. 30, 2012
AxoGen Inc. [Member]
|
Sep. 30, 2012
|
|
| Royalty Agreement Term | 8 years | |||
| Financing Receivable, Gross | $ 40.0 | $ 20.8 | ||
| Increase (Decrease) in Notes Receivables | (1.8) | |||
| Repayments of Debt | $ 11.6 | |||
| Interest Rate on Note Receivable | 5.00% |
| X | ||||||||||
|
- Definition
No authoritative reference available. No definition available.
|
| X | ||||||||||
|
- Definition
Royalty agreement term. No definition available.
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period of the amounts due from borrowers for outstanding secured or unsecured loans evidenced by a note. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount representing an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. Excludes amounts related to receivables held-for-sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations. No definition available.
|